IN VITRO ANTIMICROBIAL SUSCEPTIBILITY AND TREATMENT OUTCOMES OF MOLECULAR DIAGNOSED MYCOBACTERIUM KANSASII PULMONARY DISEASE

被引：0
|
作者：
Liu, Chia-Jung [1 ]
Hsueh, Po-Ren [1 ,2 ]
Chien, Jung-Yien [1 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan
来源：
RESPIROLOGY | 2018年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO166
引用
收藏
页码：67 / 67
页数：1
相关论文
共 50 条
  • [41] Treatment outcomes of Mycobacterium avium complex pulmonary disease according to disease severity
    Bo-Guen Kim
    Byung Woo Jhun
    Hojoong Kim
    O Jung Kwon
    Scientific Reports, 12
  • [42] DIAGNOSTIC-CRITERIA FOR PULMONARY-DISEASE CAUSED BY MYCOBACTERIUM-KANSASII AND MYCOBACTERIUM-INTRACELLULARE
    AHN, CH
    MCLARTY, JW
    AHN, SS
    AHN, SI
    HURST, GA
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1982, 125 (04): : 388 - 391
  • [43] Treatment outcomes for patients with non-tuberculous mycobacterium pulmonary disease
    Nguyen, P.
    Roach, P.
    RESPIROLOGY, 2023, 28 : 233 - 233
  • [44] Clinical characteristics and treatment outcomes of pulmonary disease caused by Mycobacterium chimaera
    Moon, Seong Mi
    Kim, Su-Young
    Jhun, Byung Woo
    Lee, Hyun
    Park, Hye Yun
    Jeon, Kyeongman
    Huh, Hee Jae
    Ki, Chang-Seok
    Lee, Nam Yong
    Shin, Sung Jae
    Koh, Won-Jung
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2016, 86 (04) : 382 - 384
  • [45] Clinical characteristics and antimicrobial susceptibility profiles of Mycobacterium abscessus and Mycobacterium massiliense pulmonary infection
    Guo, Wanru
    Shangguan, Yanwan
    Ji, Zhongkang
    Hu, Ming
    Li, Xiaomeng
    Hu, Wenjuan
    Zheng, Lin
    Huang, Shujuan
    Wang, Yuping
    Xia, Jiafeng
    Jiang, Liangxiu
    Xu, Kaijin
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 38 : 83 - 89
  • [46] Clinical characteristics and early outcomes of patients newly diagnosed with pulmonary Mycobacterium avium complex disease
    Hagiwara, Eri
    Katano, Takuma
    Isomoto, Kohsuke
    Otoshi, Ryota
    Yamakawa, Hideaki
    Okuda, Ryo
    Sekine, Akimasa
    Baba, Tomohisa
    Komatsu, Shigeru
    Ogura, Takashi
    RESPIRATORY INVESTIGATION, 2019, 57 (01) : 54 - 59
  • [47] Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004 -: Clinical features, drug susceptibility, and outcome
    Shitrit, D
    Baum, GL
    Priess, R
    Lavy, A
    Shitrit, ABG
    Raz, A
    Shlomi, D
    Daniele, B
    Kramer, MR
    CHEST, 2006, 129 (03) : 771 - 776
  • [48] SURGICAL TREATMENT OF PULMONARY DISEASE DUE TO M-KANSASII
    NEVILLE, WE
    MAGNO, M
    ZVETINA, JR
    CHEST, 1970, 58 (03) : 287 - &
  • [49] SHORT-COURSE CHEMOTHERAPY FOR PULMONARY-DISEASE CAUSED BY MYCOBACTERIUM-KANSASII
    AHN, CH
    LOWELL, JR
    AHN, SS
    AHN, SI
    HURST, GA
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1983, 128 (06): : 1048 - 1050
  • [50] In vitro susceptibility of Mycobacterium kansasii to the difluorinated quinolone sparfloxacin using a broth microdilution and macrodilution MIC system
    Royo, P
    Martín-Casabona, N
    Martínez, E
    Andonegui, M
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 1999, 3 (04) : 349 - 353
12345